- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05875974
Ph4 PSG Combined JZP258-407
April 17, 2024 updated by: Jazz Pharmaceuticals
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy
This study will assess the safety and efficacy of JZP258 (XYWAV) on sleepiness, polysomnography, and functional outcomes in patients with idiopathic hypersomnia (IH) or narcolepsy.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This prospective, multicenter, single-arm, open-label interventional study will assess the safety and efficacy of JZP258 on sleepiness, polysomnography measurements (eg, sleep stage transitions, sleep patterns, and sleep quality), daytime and nighttime symptoms, pharmacokinetics (in narcolepsy), and patient-reported outcomes that include subjective sleep quality and quality of life in patients with IH or narcolepsy.
Study Type
Interventional
Enrollment (Estimated)
186
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Clinical Trial Disclosure & Transparency
- Phone Number: 215-832-3750
- Email: ClinicalTrialDisclosure@JazzPharma.com
Study Locations
-
-
Ontario
-
Markham, Ontario, Canada, L3R 1A3
- Recruiting
- AMNDX Inc
-
Toronto, Ontario, Canada, M4P 1P2
- Recruiting
- Toronto Sleep Institute
-
Toronto, Ontario, Canada, M5S 3A3
- Recruiting
- Johda Tishon Inc
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35213
- Recruiting
- Sleep Disorders Center of Alabama
-
-
Arizona
-
Scottsdale, Arizona, United States, 85253
- Recruiting
- Perseverance Research Center, LLC
-
-
California
-
Lakewood, California, United States, 90805
- Recruiting
- Long Beach Research Institute
-
Los Angeles, California, United States, 90025
- Recruiting
- Santa Monica Clinical Trials
-
Redwood City, California, United States, 94063
- Recruiting
- Stanford School of Medicine
-
Santa Ana, California, United States, 92705
- Recruiting
- SDS Clinical Trials, Inc.
-
-
Florida
-
Altamonte Springs, Florida, United States, 32701
- Recruiting
- BioSerenity
-
Miami, Florida, United States, 33176
- Recruiting
- PharmaDev Clinical Research Institute, LLC
-
Winter Park, Florida, United States, 32789
- Recruiting
- Florida Hospital for Children
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Recruiting
- NeuroTrials Research, Inc.
-
-
Idaho
-
Nampa, Idaho, United States, 83686
- Recruiting
- Saltzer Medical Group
-
-
Michigan
-
Sterling Heights, Michigan, United States, 48314
- Recruiting
- Clinical Neurophysiology Services, P.C.
-
-
Missouri
-
Chesterfield, Missouri, United States, 63017
- Recruiting
- St. Lukes Hospital Medical Center
-
-
North Carolina
-
Gastonia, North Carolina, United States, 28054
- Recruiting
- Clinical Research of Gastonia
-
Huntersville, North Carolina, United States, 28078
- Recruiting
- Advanced Respiratory and Sleep Medicine, PLLC
-
-
Ohio
-
Cincinnati, Ohio, United States, 45212
- Recruiting
- CTI Clinical Research Center
-
Cincinnati, Ohio, United States, 45245
- Recruiting
- Intrepid Research
-
Dublin, Ohio, United States, 43017
- Recruiting
- Ohio Sleep Medicine and Neuroscience Institute
-
-
Pennsylvania
-
Abington, Pennsylvania, United States, 19001
- Recruiting
- Abington Neurological Associates, LTD
-
-
South Carolina
-
Columbia, South Carolina, United States, 29201
- Recruiting
- Bogan Sleep Consultants, LLC
-
-
Texas
-
Austin, Texas, United States, 78731
- Recruiting
- FutureSearch Trials of Neurology
-
Houston, Texas, United States, 77030
- Recruiting
- Comprehensive Sleep Medicine Associates
-
San Antonio, Texas, United States, 78229
- Recruiting
- Sleep Therapy & Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Is 18 to 75 years of age (inclusive) at the time of signing the informed consent form (ICF)
- Has a primary diagnosis of IH meeting International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria or narcolepsy (Type 1 or Type 2) meeting ICSD-3 or Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria.
- If not currently taking oxybate medication, has clinically significant symptoms of Excessive daytime sleepiness (EDS) with an ESS score > 10 at Screening Visit 1. If currently taking oxybate medication, has an ESS score > 10 at the Baseline Visit 2 polysomnography (after washout period).
- If currently treated with anticataplectics and/or alerting agents, has been taking the same dosage for at least 1 month prior to Screening Visit 1 and has no current plans to adjust the dosage during the study period.
Key Exclusion Criteria:
- Shows evidence of a previous untreated or inadequately treated sleep disorder considered by the investigator to negatively impact the conduct of the study, including sleep-disordered breathing, parasomnias, circadian rhythm sleep disorders, or restless legs syndrome determined by a previous sleep-laboratory diagnosis or interview utilizing modules of the Diagnostic Interview for Sleep Patterns and Disorders.
- Shows evidence of untreated or inadequately treated sleep-disordered breathing during Baseline Visit 2 polysomnography defined as an Apnea/Hypopnea Index (AHI) > 10, using the US Centers for Medicare and Medicaid Services rules (CMS.gov).
- Has a history or presence of any unstable or clinically significant medical condition (chronic pain condition that may impact sleep), behavioral or psychiatric disorder (including active suicidal ideation or current or past [within 1 year] major depressive episode), or history or presence of another neurologic disorder or surgical history that might affect the participant's safety and/or interfere with the conduct of the study, in the opinion of the investigator.
Has recently taken (ie, within 1 month prior to screening), is taking, or plans to take any of the following:
- A substance or medication contraindicated with XYWAV use, ie. specifically alcohol and sedative hypnotics
- A medication with a known drug-drug interaction with XYWAV
- A medication that may have similar EEG effects to XYWAV
- Medications known to have clinically significant CNS sedative effects
- Other medications, natural health products, or substances from which the participant experiences clinically significant sedation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: JZP258
Participants will self-administer an oral dose of JZP258 (XYWAV) as per label and titrate to an optimal dosage for each participant.
|
Initiate dosage per XYWAV label and titrate to variable dosage.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Epworth Sleepiness Scale (ESS) Total Score in Participants With IH and Narcolepsy Treated With XYWAV
Time Frame: Baseline up to End of Treatment (approximately 10-36 weeks)
|
Baseline up to End of Treatment (approximately 10-36 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patient Global Impression of Change (PGI-C) Score in Participants With IH and Narcolepsy Treated With XYWAV (Overall, Sleep Inertia, and Fatigue)
Time Frame: End of Treatment (approximately 10-36 weeks)
|
End of Treatment (approximately 10-36 weeks)
|
Level of Rested or Refreshed Upon Awakening in Participants With IH and Narcolepsy Treated With XYWAV (Sleep Diary)
Time Frame: Baseline up to End of Treatment (approximately 10-36 weeks)
|
Baseline up to End of Treatment (approximately 10-36 weeks)
|
Patient Global Impression of Severity (PGI-S) Score in Participants With IH and Narcolepsy Treated With XYWAV (Overall, Sleep Inertia, and Fatigue)
Time Frame: Baseline up to End of Treatment (approximately 10-36 weeks)
|
Baseline up to End of Treatment (approximately 10-36 weeks)
|
Idiopathic Hypersomnia Severity Scale (IHSS) Total Score in Participants With IH Treated With XYWAV
Time Frame: Baseline up to End of Treatment (approximately 10-21 weeks)
|
Baseline up to End of Treatment (approximately 10-21 weeks)
|
Number of Stage Shifts of Sleep in Participants With Narcolepsy Treated With XYWAV
Time Frame: Baseline up to End of Treatment (approximately 10-36 weeks)
|
Baseline up to End of Treatment (approximately 10-36 weeks)
|
Duration of Sleep Stages in Participants With Narcolepsy Treated With XYWAV
Time Frame: Baseline up to End of Treatment (approximately 10-36 weeks)
|
Baseline up to End of Treatment (approximately 10-36 weeks)
|
Percentage of Sleep Stages in Participants With Narcolepsy Treated With XYWAV
Time Frame: Baseline up to End of Treatment (approximately 10-36 weeks)
|
Baseline up to End of Treatment (approximately 10-36 weeks)
|
Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) In a Subset of Participants With Narcolepsy Treated With XYWAV
Time Frame: PK: Predose, 0.5 hour, 0.75 hour, 1 hour, 1.5 hour post-first dose and post-second dose, 6 hour post-first dose, 8 hour post-first dose
|
PK: Predose, 0.5 hour, 0.75 hour, 1 hour, 1.5 hour post-first dose and post-second dose, 6 hour post-first dose, 8 hour post-first dose
|
Pharmacokinetic Parameter Area Under the Concentration-Time Curve From time 0 to Infinity (AUC0-inf) In a Subset of Participants With Narcolepsy Treated With XYWAV
Time Frame: PK: Predose, 0.5 hour, 0.75 hour, 1 hour, 1.5 hour post-first dose and post-second dose, 6 hour post-first dose, 8 hour post-first dose
|
PK: Predose, 0.5 hour, 0.75 hour, 1 hour, 1.5 hour post-first dose and post-second dose, 6 hour post-first dose, 8 hour post-first dose
|
Number of Nocturnal Awakenings and Nocturnal Arousals in Participants With Narcolepsy Treated With XYWAV
Time Frame: Baseline up to End of Treatment (approximately 10-36 weeks)
|
Baseline up to End of Treatment (approximately 10-36 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 27, 2023
Primary Completion (Estimated)
November 1, 2024
Study Completion (Estimated)
November 1, 2024
Study Registration Dates
First Submitted
May 16, 2023
First Submitted That Met QC Criteria
May 16, 2023
First Posted (Actual)
May 25, 2023
Study Record Updates
Last Update Posted (Estimated)
April 18, 2024
Last Update Submitted That Met QC Criteria
April 17, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- JZP258-407
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Narcolepsy
-
University of Dublin, Trinity CollegeSt. James's Hospital, IrelandSuspendedNarcolepsy | Hypersomnolence | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Narcolepsy 1 | Narcolepsy and HypersomniaIreland
-
Northwestern UniversityActive, not recruitingNarcolepsy | Narcolepsy Type 1 | Narcolepsy Without Cataplexy | Narcolepsy With Cataplexy | Narcolepsy Type 2United States
-
NLS PharmaceuticsCompletedNarcolepsy | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
-
Boston Children's HospitalAmerican Academy of Sleep MedicineRecruitingIdiopathic Hypersomnia | Narcolepsy Type 1 | Narcolepsy Type 2United States
-
NLS PharmaceuticsNot yet recruitingNarcolepsy Type 1 | Narcolepsy With Cataplexy
-
TakedaRecruitingNarcolepsy Type 1 | Narcolepsy Type 2Spain, Germany, United States, Italy, Netherlands, Japan, France, Norway, Australia, Finland, Switzerland, Sweden
-
Northwestern UniversityNational Center for Complementary and Integrative Health (NCCIH)CompletedNarcolepsy | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
-
BioprojetActive, not recruitingNarcolepsy Without Cataplexy | Narcolepsy With CataplexyFrance, Italy, Russian Federation, Finland, Netherlands
-
TakedaTerminatedNarcolepsy Type 1 (NT1) | Narcolepsy Type 2 (NT2)China, United States, Korea, Republic of, France, Italy, Finland, Spain, Czechia, Canada, Japan, Hungary, Netherlands
-
Emory UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingIdiopathic Hypersomnia | Narcolepsy Without Cataplexy | Narcolepsy With CataplexyUnited States
Clinical Trials on JZP258 (XYWAV)
-
Jazz PharmaceuticalsRecruitingNarcolepsyUnited States, Belgium, Spain, France, Italy, Czechia
-
Jazz PharmaceuticalsCompleted
-
Jazz PharmaceuticalsCompleted
-
Mayo ClinicRecruiting